U.S. markets close in 2 hours 44 minutes

Fluidigm Corporation (FLDM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.9400+0.3500 (+7.63%)
As of 1:15PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close4.5900
Open4.0600
Bid4.9600 x 1300
Ask4.9800 x 800
Day's Range4.0300 - 5.0000
52 Week Range3.3300 - 12.4500
Volume2,748,388
Avg. Volume2,421,506
Market Cap370.316M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.7360
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period
    GlobeNewswire

    Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period

    Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the first quarter ended March 31, 2021. “We delivered solid performance in the quarter as we worked to transform our microfluidics and mass cytometry franchises into durable growth platforms,” said Chris Linthwaite, President and CEO. “Fundamental changes in our traditional markets will enable us to focus on next-generation health care decision tools, generate higher recurring revenues and capitalize on a significant addressable market opportunity. We are acting with urgency to cultivate new revenue streams and partnerships in our core markets as vaccinations increase and the demand for COVID testing and related revenue wanes. “With new publications, new data and expansion into new markets, our mass cytometry business has become increasingly important for health care decision making. Looking ahead, we expect that customers will continue to recognize the numerous translational and clinical research applications of our comprehensive platform. “Our Vision 2025 strategy focuses on innovation, establishing and mobilizing new markets and channels and seeking collaborations to deliver enhanced value for our customers and stockholders,” continued Linthwaite. “We are confident that our flexibility, efficiency, scalability and novel testing strategies position us well for the future.” Recent Highlights The company delivered growth across all geographies versus the prior year period.A $1 million order was closed from a major microfluidics customer serving the public education market with COVID-19 testing.At quarter end, 144 clinical trials were underway using Fluidigm® proprietary CyTOF® technology.Total publications and reviews involving CyTOF technology exceeded 1,500, including 105 publications and reviews for Imaging Mass Cytometry™, as of the end of Q1 2021.Data published in the prestigious Nature Communications journal demonstrate the potential of CyTOF and Imaging Mass Cytometry for predicting individual patient response to oncology therapies. Product Innovation A new COVID-19 mutation detection reagent kit will be made available this quarter and will enable customers to identify pathogen Variants of Concern, including UK, South Africa and Brazil variants.Fluidigm plans to host a virtual investor event on May 24 including customer guest speakers showcasing the effectiveness of Fluidigm’s technology, applications and proactive response to emerging customer needs. First Quarter 2021 Financial Results Total revenue was $32.8 million for the quarter ended March 31, 2021, representing a 19 percent increase from $27.6 million in the first quarter of 2020. Product and service revenue increased 28 percent to $31.0 million and included $6.5 million of COVID-19 revenue. Total revenue also included $1.8 million of other revenue. GAAP net loss for the quarter was $18.8 million, compared with a GAAP net loss of $16.0 million for the first quarter of 2020. Non-GAAP net loss was $11.1 million for the quarter, compared with a $9.4 million non-GAAP net loss for the first quarter of 2020. Cash and cash equivalents and restricted cash as of March 31, 2021, totaled $50.8 million. This compared to $69.5 million at December 31, 2020. A reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release. Supplemental Financial Information updated through March 31, 2021, has been posted on our website concurrent with this release. Annual 2021 Guidance In view of the recent decline in, and the high degree of variability in the outlook for, COVID-19 testing, the company is revising its revenue and net loss guidance to reflect lower revenue from COVID-19 testing partially offset by higher anticipated revenue from the company's base business (excluding COVID-19) due to the improving outlook and activities in support of growth, including the launch of new products. ($ in millions)20202021 ActualsPrevious GuidanceAnnualGuidanceProduct & Service Revenue Base business$100.1 $108 $112 $116 $117 COVID-19$22.4 $32 $38 $14 $18 Total Product & Service Revenue$122.5 $140 $150 $130 $135 Other Revenue$15.6 $4 $5 $4 $5 Total Revenue$138.1 $144 $155 $134 $140 Year-over-year growth Base business-14% 8% 12% 16% 17% COVID-19NM 43% 70% -38% -20% Total Product & Service Revenue5% 14% 22% 6% 10% Total Revenue18% 4% 12% -3% 1% GAAP net loss of $57 million to $60 million.Non-GAAP net loss of $24 million to $27 million. Q2 2021 Guidance Product and service revenue of approximately $29 million to $31 million, or approximately 29 percent to 38 percent year-over-year growth, Base product and service revenue (excluding COVID-19) of approximately $26 million to $27 million, or approximately 28 percent to 33 percent year-over-year growth. Other revenue of approximately $1 million.Total revenue of approximately $30 million to $32 million. Conference Call Information Fluidigm will host a conference call today, May 6, 2021, at 2:00 p.m. PT, 5:00 p.m. ET, to discuss first quarter 2021 financial results and operational progress. Individuals interested in listening to the conference call may do so by dialing the following: US domestic callers: (877) 556-5248 Outside US callers: (720) 545-0029Please reference Conference ID: 6019148 A live webcast of the conference call will be available online from the Investor Relations page of the company’s website at Events & Presentations. The link will not be active until 1:45 p.m. PT, 4:45 p.m. ET, on May 6, 2021. The webcast will be archived on the Fluidigm Investor Relations page at investors.fluidigm.com. Statement Regarding Use of Non-GAAP Financial InformationFluidigm has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three-month periods ended March 31, 2021, and March 31, 2020. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Our estimates of forward-looking non-GAAP operating loss exclude estimates for stock-based compensation expense and depreciation and amortization; loss on disposal of property and equipment; future changes relating to developed and acquired technologies; other intangible assets; and income taxes, among other items, certain of which are presented in the tables accompanying our earnings release. A reconciliation of adjusted guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding certain expenses that may be incurred in the future. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our control. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Fluidigm encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release. Use of Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding market trends and Fluidigm’s ability to introduce products, grow revenues, and access markets based on such trends; Fluidigm’s ability to enter into new collaborations and partnerships; the adoption of Fluidigm technology and products for translational and clinical research; strategic plans to access new markets and channels; anticipated new product introductions and company events; and revenue and net loss guidance for future periods. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results; declines in revenue from COVID-19 testing; the possible loss of key employees, customers, or suppliers; uncertainties in contractual relationships; customers and prospective customers continuing to curtail or suspend activities utilizing our products; our ability and/or the ability of the research institutions utilizing our products and technology to obtain and maintain Emergency Use Authorization from the FDA and any other requisite authorizations or approvals to use our products and technology for diagnostic testing purposes; potential changes in priorities or requirements for Emergency Use Authorizations or other regulatory authorizations or approvals; potential limitations of any Emergency Use Authorization or other regulatory authorizations or approvals; potential changes in the priorities of government agencies; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; Fluidigm research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm's business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2020, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law. About Fluidigm Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com. Fluidigm, the Fluidigm logo, Advanta, CyTOF, and Imaging Mass Cytometry are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. Available InformationWe use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Contacts:Investors:Peter DeNardo415 389 6400ir@fluidigm.com Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com FLUIDIGM CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(Unaudited) Three Months Ended March 31, 2021 2020Revenue: Product revenue $24,728 $18,981 Service revenue 6,286 5,186 Product and service revenue 31,014 24,167 Other revenue (Note 1) 1,780 3,450 Total revenue 32,794 27,617 Costs and expenses: Cost of product revenue 11,663 9,640 Cost of service revenue 2,090 1,525 Cost of product and service revenue 13,753 11,165 Research and development 10,753 8,699 Selling, general and administrative 27,608 22,695 Total costs and expenses 52,114 42,559 Loss from operations (19,320) (14,942)Interest expense (887) (900)Other expense, net (285) (818)Loss before income taxes (20,492) (16,660)Income tax benefit 1,671 680 Net loss $(18,821) $(15,980)Net loss per share, basic and diluted $(0.25) $(0.23)Shares used in computing net loss per share, basic and diluted 74,707 70,458 Note: (1) Other revenue includes development revenue, license revenue, royalty revenue and grant revenue. FLUIDIGM CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited) March 31,2021 December 31,2020 (1)ASSETS Current assets: Cash and cash equivalents (Note 2) $49,744 $68,520 Accounts receivable, net 15,412 25,423 Inventories, net 21,892 19,689 Prepaid expenses and other current assets (Note 2) 9,279 4,031 Total current assets 96,327 117,663 Property and equipment, net 23,784 17,531 Operating lease right-of-use assets, net 37,245 38,114 Other non-current assets (Note 2) 4,386 4,680 Developed technology, net 37,000 40,206 Goodwill 106,456 106,563 Total assets $305,198 $324,757 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $12,552 $9,220 Accrued compensation and related benefits 8,693 13,787 Operating lease liabilities, current 3,025 2,973 Other accrued liabilities 15,037 14,794 Deferred revenue, current 14,222 13,475 Total current liabilities 53,529 54,249 Convertible notes, net 53,837 54,224 Deferred tax liability, net 6,732 8,697 Operating lease liabilities, non-current 37,419 38,178 Deferred revenue, non-current 7,202 7,990 Deferred grant income, non-current 22,167 21,036 Other non-current liabilities 1,374 1,333 Total liabilities 182,260 185,707 Total stockholders' equity 122,938 139,050 Total liabilities and stockholders' equity $305,198 $324,757 Notes: (1) Derived from audited consolidated financial statements (2) Cash and cash equivalents, available for sale securities and restricted cash consist of: Cash and cash equivalents $49,744 $68,520 Restricted cash (included in prepaid and other current assets, and other non-current assets) 1,016 1,016 Total cash and cash equivalents, available for sale securities and restricted cash $50,760 $69,536 FLUIDIGM CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)(Unaudited) Three Months Ended March 31, 2021 2020Operating activities Net loss $(18,821) $(15,980)Stock-based compensation expense 3,677 2,366 Amortization of developed technology 2,983 2,968 Depreciation and amortization 934 1,092 Other non-cash items 610 599 Changes in assets and liabilities, net (2,284) 4,660 Net cash used in operating activities (12,901) (4,295) Investing activities Acquisition, net of cash acquired — (5,154)Proceeds from NIH Contract 2,000 — Proceeds from sales and maturities of investments — 23,644 Purchases of property and equipment (6,923) (1,030)Net cash provided by (used in) investing activities (4,923) 17,460 Financing activities Repayment of long-term debt (501) — Payments for taxes related to net share settlement of equity awards (525) (146)Payment of debt issuance costs — (357)Net cash used in financing activities (1,026) (503) Effect of foreign exchange rate fluctuations on cash and cash equivalents 74 (331)Net increase (decrease) in cash, cash equivalents and restricted cash (18,776) 12,331 Cash, cash equivalents and restricted cash at beginning of period 69,536 23,736 Cash, cash equivalents and restricted cash at end of period $50,760 $36,067 Cash and cash equivalents, restricted cash and available for sale securities consist of: Cash and cash equivalents $49,744 $34,992 Short-term investments — 13,493 Restricted cash (included in prepaid and other current assets, and other non-current assets) 1,016 1,075 Total cash and cash equivalents, available for sale securities and restricted cash $50,760 $49,560 FLUIDIGM CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION(In thousands, except per share amounts)(Unaudited) ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET LOSS Three Months Ended March 31, 2021 2020 Net loss (GAAP) $(18,821) $(15,980)Stock-based compensation expense 3,677 2,366 Amortization of developed technology (a) 2,983 2,968 Depreciation and amortization 934 1,092 Interest expense (b) 887 900 Loss on extinguishment of debt 9 — Benefit from acquisition related income taxes (c) (742) (742)Net loss (Non-GAAP) $(11,073) $(9,396)Shares used in net loss per share calculation - basic and diluted (GAAP and Non-GAAP) 74,707 70,458 Net loss per share - basic and diluted (GAAP) $(0.25) $(0.23)Net loss per share - basic and diluted (Non-GAAP) $(0.15) $(0.13) ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP PRODUCT AND SERVICE MARGIN Three Months Ended March 31, 2021 2020Product and service gross profit (GAAP) $17,261 $13,002 Amortization of developed technology (a) 2,800 2,800 Depreciation and amortization (d) 420 393 Stock-based compensation expense (d) 98 71 Product and service gross profit (Non-GAAP) $20,579 $16,266 Product and service margin percentage (GAAP) 55.7% 53.8%Product and service margin percentage (Non-GAAP) 66.4% 67.3% ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP OPERATING EXPENSES Three Months Ended March 31, 2021 2020Operating expenses (GAAP) $38,361 $31,394 Stock-based compensation expense (e) (3,579) (2,295)Depreciation and amortization (e) (697) (867)Operating expenses (Non-GAAP) $34,085 $28,232 ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP LOSS FROM OPERATIONS Three Months Ended March 31, 2021 2020Loss from operations (GAAP) $(19,320) $(14,942)Stock-based compensation expense 3,677 2,366 Amortization of developed technology (a) 2,983 2,968 Depreciation and amortization (e) 934 1,092 Loss from operations (Non-GAAP) $(11,726) $(8,516) (a) represents amortization of developed technology in connection with the DVS acquisition(b) represents interest expense, primarily on convertible debt(c) represents the tax impact on the purchase of intangible assets in connection with the DVS acquisition(d) represents expense associated with cost of product revenue(e) represents expense associated with research and development, selling, general and administrative activities

  • Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology
    GlobeNewswire

    Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

    Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to TherapiesSOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of data that further validate the potential of its mass cytometry technologies, CyTOF® and Imaging Mass Cytometry™ (IMC™), to provide new approaches to evaluating cancer therapies in animal models using human tumor xenografts, potentially identifying which patients are most likely to benefit from specific targeted cancer therapies. The research was led by scientists at the Cancer Research UK (CRUK) Cambridge Institute at the University of Cambridge in collaboration with the Imaging and Molecular Annotation of Xenografts and Tumors (IMAXT) Cancer Grand Challenges Consortium, and the data have been published online in Nature Communications. This work was funded by Cancer Grand Challenges, AstraZeneca, a European Research Council Advanced Grant and the EU Marie Sklodowska-Curie Research program. Researchers developed a panel of 33 antibodies designed to detect and differentiate human tumor cells from the surrounding mouse cells and to detect activation of cancer-related signaling pathways as well as markers of cell death (including programmed cell death). The breast cancer mass cytometry (BCMC) antibody panel was validated in a variety of well-characterized cell lines and then used to evaluate 53 human breast cancer xenograft samples capturing the diversity of breast cancers observed in patients, as previously shown and published in Cell (Bruna et al., 2016). This large biobank of human tumor xenografts was established at the CRUK Cambridge Institute by implanting human tumor tissue into a mouse and is used as a powerful preclinical platform to accelerate drug development, allowing high-content drug screens both in vitro and in vivo. Xenograft samples were examined via suspension mass cytometry and IMC to evaluate the presence and distribution of distinct cell phenotypes in breast cancer tumors and their surrounding microenvironments. Results of these analyses identified several unique phenotypic profiles not previously detected using genomic or gene expression assessments, and also correlated these phenotypes with breast cancer molecular features. The study also used drug screening data generated in the same xenograft platform to correlate BCMC-determined cellular phenotypes with response or resistance to specific therapies (caldaslab.cruk.cam.ac.uk/bcape/). These analyses demonstrated that mass cytometry-based phenotypic footprints captured distinct features not detected using typical genetic and genomic evaluations. Examples include the identification of two distinct types of triple-negative breast cancers, which are typically aggressive and hard to treat, and the determination that each group has distinct drug response profiles when treated with standard of care chemotherapy and targeted therapies. Also, a specific cellular architecture (luminal cell clusters) was identified and was correlated with response to the PI3K-inhibitors, a class of drugs for which genomic analysis is a poor predictor of response. “To date, most studies on tumor heterogeneity have focused on genetic diversity, and only a handful have evaluated phenotypic diversity at the protein level. We employed mass cytometry to identify and characterize core cellular phenotypes in a large cohort of breast cancer xenografts, part of a well-characterized preclinical platform in our lab,” said Dimitra Georgopoulou, PhD, Research Associate at the CRUK Cambridge Institute and lead author of the publication. “Integrating phenotypic data with molecular and drug response data from the same xenografts, we found that phenotypic heterogeneity at the cellular level is a critical determinant of drug response. This finding has major implications in both preclinical and clinical efforts in breast cancer.” “In the current study we also combined the data from the suspension mass cytometry approach with Imaging Mass Cytometry performed on the same xenograft models,” said Dario Bressan, PhD, Head of the IMAXT Laboratory at the CRUK Cambridge Institute. “In a previous work (Ali et al., 2020), we also performed IMC on the primary tumor from which these xenografts were generated. This was really key to expanding our understanding of how specific cell phenotypes are spatially distributed and their clinical relevance. This approach allowed us to map the cellular phenotypes across mass cytometry platforms and from xenograft to clinical samples: something quite unique which was never successfully attempted before.” An additional key finding from the study is the demonstration that defined cell phenotypes with different responses to treatment co-exist within a single tumor. Importantly, this phenotypic variability does not appear to correlate with genetic intra-tumor variability. This finding has critical implications for both preclinical drug screening methods and translational medicine, suggesting that new combination therapies may need to be developed in order to address multiple cell types within an individual tumor. The authors suggest that mass cytometry could potentially be used to directly profile biopsy samples from patients undergoing therapy to more accurately assess their response to treatment and determine if continued therapy is likely to provide benefit. “Our findings open the door to new and potentially more informative models for evaluating cancer therapy and for predicting an individual patient’s response to potential therapies, both of which are important for enabling precision oncology medicine,” said Georgopoulou. “This study underscores the importance of global collaboration among leaders in diverse aspects of cancer research to yield breakthroughs for the entire oncology research community,” said Chris Linthwaite, Fluidigm President and CEO. “Fluidigm is committed to harnessing the power of our technologies to improve life, and this important study demonstrates our ability to support cutting-edge preclinical and translational medicine approaches that truly transform our understanding of cancer and identify new paths for improving care and outcome. These data highlight the true benefits of integrating IMC and mass cytometry to create dual-mode assessments and workflows that enable efficient generation of rich datasets.” Learn more: cancergrandchallenges.org/teams/imaxt About FluidigmFluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com. Fluidigm, the Fluidigm logo, Advanta, CyTOF, Imaging Mass Cytometry, and IMC are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding applications for and benefits of Fluidigm products in cancer research. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results; company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; competition; and reductions in research and development spending or changes in budget priorities by customers. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2020, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law. Available InformationWe use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Fluidigm Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com Investors:Peter DeNardo415 389 6400 ir@fluidigm.com

  • How Many Fluidigm Corporation (NASDAQ:FLDM) Shares Do Institutions Own?
    Simply Wall St.

    How Many Fluidigm Corporation (NASDAQ:FLDM) Shares Do Institutions Own?

    Every investor in Fluidigm Corporation ( NASDAQ:FLDM ) should be aware of the most powerful shareholder groups...